Abstract
Association between gastric inhibitory polypeptide receptor polymorphism, rs10423928, and body mass index in olanzapine-treated schizophrenia was examined. Body mass index change for the A/T+A/A genotypes was significantly higher than that for the T/T genotype. rs10423928 may predict weight gain in schizophrenia.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antipsychotic Agents / therapeutic use*
-
Benzodiazepines / therapeutic use*
-
Body Mass Index
-
Body Weight / drug effects
-
Body Weight / genetics*
-
Female
-
Genotype
-
Humans
-
Male
-
Middle Aged
-
Olanzapine
-
Pharmacogenetics*
-
Polymorphism, Single Nucleotide / genetics*
-
Receptors, Gastrointestinal Hormone / genetics*
-
Schizophrenia* / drug therapy
-
Schizophrenia* / genetics
-
Schizophrenia* / physiopathology
-
Young Adult
Substances
-
Antipsychotic Agents
-
Receptors, Gastrointestinal Hormone
-
Benzodiazepines
-
gastric inhibitory polypeptide receptor
-
Olanzapine